Group 1 - The resignation of Han Chunlin, Vice President of Ruikang Pharmaceutical, is due to personal reasons and will not affect the board's operations or normal business activities [2][4] - Han Chunlin, born in 1993, has been with Ruikang Pharmaceutical since 2013, holding various positions and becoming Vice President in 2023 [3] - His departure adds uncertainty to the company, which is already facing operational pressures, with revenue declining from 27.2 billion in 2020 to 7.97 billion in 2024 [4] Group 2 - Han Chunlin's salary for 2024 was 904,400 yuan, significantly higher than the average of 467,300 yuan for other senior executives [3] - The company has been under pressure, with stock prices consistently below net asset value and previous attempts by the controlling shareholder to transfer shares failing [4] - Ruikang Pharmaceutical, established in 2004, is a leading player in the domestic pharmaceutical distribution sector, involved in drug distribution, medical devices, and digital healthcare [4]
瑞康医药“少东家”韩春林辞任董事、副总裁 薪酬远超其他董监高